此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PKU Microtablets Case Studies

2026年6月23日 更新者:Nutricia UK Ltd

Evaluating the Adherence, Tolerance, Acceptability and Safety of a New Amino Acid Based, Microtablet Protein Substitute in PKU: a Case Study Series

Phenylalanine (Phe) free protein substitutes are typically presented in ready to drink liquid or powder format and are made up with water to a set volume. Despite recent advancements related to the taste, scent and texture of commercially available protein substitutes, a proportion of PKU patients choose to consume tablet-based protein substitutes. Protein substitutes in tablet format may help overcome taste, scent and texture concerns associated with powdered and liquid preparations. Indeed, previous research has shown that protein substitute tablets are an effective strategy to manage PKU in children, teenagers and adults. Nonetheless, the daily burden and discipline required often impedes compliance, especially alongside the restrictive low-protein diet. Achieving compliance with multivitamin supplements when given alongside protein substitutes therefore becomes especially challenging. This is particularly true for adolescent, adult and maternal populations.

PKU Microtablets have recently been developed. PKU Microtablets are a new phenylalanine-free tablet protein substitute combined with vitamins, minerals and trace elements. As patient acceptability is fundamental to the successful use of any protein substitute, investigation is needed to assess the compliance, tolerance and acceptability of PKU Microtablets as part of a low phenylalanine dietary regimen in PKU patients.

This series of case-studies aims to evaluate the gastrointestinal tolerance, acceptability, compliance, and safety of this protein substitute in both adults and children from 4 years. These case studies will last 29 days in total, including a 1-day baseline period followed by a 28-day intervention period. The case studies will be conducted across multiple specialist metabolic centres in the UK.

研究概览

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Bristol、英国
        • University Hospitals Bristol and Weston NHS Foundation Trust

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Male or female
  • Over 4 years of age
  • Patients diagnosed with any phenotype of PKU characterised by hyperphenylalaninaemia
  • Have been compliant in taking at least one protein substitute, providing at least 20g protein equivalent, for at least 1 month prior to trial commencement
  • Have a prescribed daily phenylalanine allowance for PKU
  • Written or electronic informed consent from patient, and/or from parent/caregiver if applicable
  • Participants who are anticipated to be able to take at least 20g protein equivalent of the case study product per day

Exclusion Criteria:

  • Pregnant or lactating
  • Requiring parenteral nutrition
  • Major hepatic or renal dysfunction
  • Participation in other studies within 1 month prior to entry of this study
  • Allergy to any of the study product ingredients
  • Investigator concern around willingness/ability of patient or parent/caregiver to comply with protocol requirement
  • Treatment with Sapropterin dihydrochloride for less than 6 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PKU Microtabet intervention product
Dietary Supplement: PKU Microtablet intervention product
PKU Microtablet intervention product

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Gastro-intetsinal tolerance
大体时间:Measured at baseline (day 1) and end of intervention (day 29)
GI tolerance will be recorded by the Dietitian at baseline on Day 1 and at the end of the case study period (Day 29). GI tolerance will be recorded using a standardised questionnaire to capture perceived severity (none, mild, moderate or severe) of common gastrointestinal symptoms (diarrhoea, constipation, bloating, abdominal discomfort, vomiting and nausea).
Measured at baseline (day 1) and end of intervention (day 29)

次要结果测量

结果测量
措施说明
大体时间
遵守
大体时间:在基线(第1天)和干预结束时测量(第29天)
符合建议摄入患者通常的蛋白质替代品(基线期间)和研究产品(在案例研究期间)的摄入量,将由营养师在基线时(第1天)和案例研究结束时评估(第29天)。 将要求患者和/或父母/护理人员回忆起过去24小时的蛋白质替代品的数量,平均而言。 这将与他们的营养师建议消耗的金额进行比较。 营养师管理患者护理的每日数量将在案例研究开始时记录,并且在案例研究期间对此处方的任何更改也将被记录。
在基线(第1天)和干预结束时测量(第29天)
Acceptability
大体时间:Measured at baseline (day 1) and end of intervention (day 29)
Acceptability (ease of use and liking) of the patients' usual protein substitute and the study product will be assessed by the Dietitian at baseline (Day 1) and the end of the case study period (Day 29) by a series of questions posed to the patient and/or parent/caregiver. Acceptability questions will assess the patient's sensory experience, ease of use, tolerance, and overall self-rated acceptability on a 5-point Likert scale from Terrible (worst) to Great (best).
Measured at baseline (day 1) and end of intervention (day 29)
Blood Phe and Tyrosine
大体时间:Day 2 (baseline) and day 29 (end of intervention)
Participants will be required to provide a total of two fasting fingerprick blood samples as dried blood spots; one on the first day of the intervention period (Day 2) before consuming any of the case study product, and one at the end of the intervention period (Day 29). These tests will be conducted in addition to any usual blood tests the participants conduct as part of their usual disease management, which vary in frequency with the age of the participant and the local policy. Dietitians will also be asked to describe the patient's metabolic control during the case study period.
Day 2 (baseline) and day 29 (end of intervention)
Anthropometry - Height
大体时间:Day 1 (baseline) and day 29 (end of intervention)
Height will be measured, using standard methods, recorded to the nearest 0.1cm (at baseline only) and used to calculate body mass index (BMI, kg/m2).
Day 1 (baseline) and day 29 (end of intervention)
Anthropometry - Weight
大体时间:Day 1 (baseline) and day 29 (end of intervention)
For safety purposes, at baseline (Day 1) and at the end of the case study (Day 29), body weight (kg) will be measured where possible using standard methods, recorded to the nearest 0.1kg using a weighing scale without heavy clothing.
Day 1 (baseline) and day 29 (end of intervention)
Patient History
大体时间:Day 1 (baseline) and day 29 (end of intervention)
A detailed patient history will be recorded at baseline to assess previous compliance to protein substitutes, relevant medical and clinical issues, medication(s) prescribed, and any other relevant information related to the patient's condition or dietary management.
Day 1 (baseline) and day 29 (end of intervention)
Safety/ Adverse events
大体时间:Throughout the case study series (day 1 to day 29).
All adverse events will be recorded, throughout the case study.
Throughout the case study series (day 1 to day 29).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Gary Hubbard, Dr、Nutricia, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年6月17日

首先提交符合 QC 标准的

2026年6月23日

首次发布 (实际的)

2026年6月26日

研究记录更新

最后更新发布 (实际的)

2026年6月26日

上次提交的符合 QC 标准的更新

2026年6月23日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅